Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT05172960




Registration number
NCT05172960
Ethics application status
Date submitted
14/12/2021
Date registered
29/12/2021
Date last updated
1/04/2024

Titles & IDs
Public title
ALLIANCE: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve
Scientific title
Safety and Effectiveness of Balloon-Expandable Bioprosthetic SAPIEN X4 Transcatheter Heart Valve
Secondary ID [1] 0 0
2021-05
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Aortic Stenosis, Severe 0 0
Condition category
Condition code
Cardiovascular 0 0 0 0
Diseases of the vasculature and circulation including the lymphatic system

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Devices - SAPIEN X4 THV

Experimental: TAVR - Main Cohort - Subjects will undergo transcatheter aortic valve replacement (TAVR)

Experimental: TAVR - Bicuspid Registry - Subjects with bicuspid aortic valve morphology will undergo TAVR


Treatment: Devices: SAPIEN X4 THV
Implantation of the SAPIEN X4 valve
Intervention code [1] 0 0
Treatment: Devices
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Non-hierarchical composite of death and stroke
Timepoint [1] 0 0
1 year
Secondary outcome [1] 0 0
Favorable outcome per VARC-3: Composite of 1) alive, 2) Kansas City Cardiomyopathy Questionnaire (KCCQ) score = 60, and 3) KCCQ score decrease =10 points from baseline
Timepoint [1] 0 0
1 year
Secondary outcome [2] 0 0
Paravalvular leak
Timepoint [2] 0 0
30 days
Secondary outcome [3] 0 0
New permanent pacemaker implantation
Timepoint [3] 0 0
30 days

Eligibility
Key inclusion criteria
1. Severe, calcific AS

2. Native aortic annulus size suitable for SAPIEN X4 THV

3. NYHA functional class = II

4. The subject has been informed of the nature of the study, agrees to its provisions and
has provided written informed consent.
Minimum age
No limit
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Anatomical characteristics that would preclude safe femoral placement of the
introducer sheath or safe passage of the delivery system

2. Aortic valve is unicuspid, bicuspid or non-calcified

3. Pre-existing mechanical or bioprosthetic valve in any position

4. Severe aortic regurgitation (> 3+)

5. Severe mitral regurgitation (> 3+) or = moderate mitral stenosis

6. Need for mitral, tricuspid or pulmonic valve intervention within the next 12 months

7. Left ventricular ejection fraction < 20%

8. Cardiac imaging evidence of intracardiac mass, thrombus or vegetation

9. Left ventricular outflow tract calcification that would increase the risk of annular
rupture or significant PVL after THV implantation

10. Increased risk of coronary artery obstruction after THV implantation

11. Myocardial infarction within 30 days prior to the study procedure

12. Hypertrophic cardiomyopathy with subvalvular obstruction

13. Subjects with planned concomitant ablation for atrial fibrillation

14. Complex coronary artery disease (CAD) that cannot be optimally treated by percutaneous
coronary intervention (PCI)

15. Any surgical or transcatheter procedure within 30 days prior to the study procedure
(unless part of planned strategy for treatment of CAD). Implantation of a permanent
pacemaker or implantable cardioverter defibrillator (ICD) is not considered an
exclusion.

16. Any planned surgical or transcatheter intervention to be performed within 30 days
following the study procedure (unless part of planned strategy for treatment of CAD)

17. Endocarditis within 180 days prior to the study procedure

18. Stroke, transient ischemic attack or neurological signs and symptoms attributed to
carotid or vertebrobasilar disease within 90 days prior to the study procedure

19. Hemodynamic or respiratory instability requiring inotropic or mechanical support
within 30 days prior to the study procedure

20. Renal insufficiency and/or renal replacement therapy

21. Leukopenia, anemia, thrombocytopenia

22. Inability to tolerate or condition precluding treatment with antithrombotic therapy

23. Hypercoagulable state or other condition that increases risk of thrombosis

24. Absolute contraindications or allergy to iodinated contrast that cannot be adequately
treated with premedication

25. Subject refuses blood products

26. BMI > 50 kg/m2

27. Estimated life expectancy < 24 months

28. Female who is pregnant or lactating

29. Active SARS-CoV-2 infection or previously diagnosed with COVID-19 with sequelae that
could confound endpoint assessments

30. Participating in another investigational drug or device study that has not reached its
primary endpoint

31. Subject considered to be part of a vulnerable population

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Not Applicable
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
20/06/2022
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/12/2034
Actual
Sample size
Target
915
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
QLD,SA
Recruitment hospital [1] 0 0
St. Andrews War Memorial Hospital - Spring Hill
Recruitment hospital [2] 0 0
Royal Adelaide Hospital - Adelaide
Recruitment hospital [3] 0 0
The Royal Melbourne Hospital - Parkville
Recruitment postcode(s) [1] 0 0
4000 - Spring Hill
Recruitment postcode(s) [2] 0 0
5000 - Adelaide
Recruitment postcode(s) [3] 0 0
3050 - Parkville
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Colorado
Country [3] 0 0
United States of America
State/province [3] 0 0
Connecticut
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Georgia
Country [6] 0 0
United States of America
State/province [6] 0 0
Illinois
Country [7] 0 0
United States of America
State/province [7] 0 0
Indiana
Country [8] 0 0
United States of America
State/province [8] 0 0
Kansas
Country [9] 0 0
United States of America
State/province [9] 0 0
Maryland
Country [10] 0 0
United States of America
State/province [10] 0 0
Massachusetts
Country [11] 0 0
United States of America
State/province [11] 0 0
Michigan
Country [12] 0 0
United States of America
State/province [12] 0 0
Minnesota
Country [13] 0 0
United States of America
State/province [13] 0 0
Missouri
Country [14] 0 0
United States of America
State/province [14] 0 0
Montana
Country [15] 0 0
United States of America
State/province [15] 0 0
New Hampshire
Country [16] 0 0
United States of America
State/province [16] 0 0
New Jersey
Country [17] 0 0
United States of America
State/province [17] 0 0
New York
Country [18] 0 0
United States of America
State/province [18] 0 0
North Carolina
Country [19] 0 0
United States of America
State/province [19] 0 0
Ohio
Country [20] 0 0
United States of America
State/province [20] 0 0
Oklahoma
Country [21] 0 0
United States of America
State/province [21] 0 0
Oregon
Country [22] 0 0
United States of America
State/province [22] 0 0
Pennsylvania
Country [23] 0 0
United States of America
State/province [23] 0 0
Tennessee
Country [24] 0 0
United States of America
State/province [24] 0 0
Texas
Country [25] 0 0
United States of America
State/province [25] 0 0
Virginia
Country [26] 0 0
United States of America
State/province [26] 0 0
Washington
Country [27] 0 0
Canada
State/province [27] 0 0
British Columbia
Country [28] 0 0
Canada
State/province [28] 0 0
Ontario
Country [29] 0 0
Canada
State/province [29] 0 0
Quebec
Country [30] 0 0
New Zealand
State/province [30] 0 0
Christchurch

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Edwards Lifesciences
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The objective of this study is to establish the safety and effectiveness of the Edwards
SAPIEN X4 Transcatheter Heart Valve (THV) in subjects with symptomatic, severe, calcific
aortic stenosis (AS).
Trial website
https://clinicaltrials.gov/ct2/show/NCT05172960
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Tamim M. Nazif, MD
Address 0 0
Columbia University
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Edwards THV Clinical Affairs
Address 0 0
Country 0 0
Phone 0 0
949-250-2500
Fax 0 0
Email 0 0
THV_CT.gov@Edwards.com
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT05172960